Targeting the multifaceted BRAF in cancer: New directions (IMAGE)
Caption
Figure 1:
(A) BRAF alteration frequencies, according to GENIE 15.1, among select solid organ tumors (glioma, 11%; thyroid cancer, 44%; non-small cell lung cancer, 6%; bladder cancer, 5%; prostate cancer, 3%; colorectal cancer, 12%; pancreatic cancer, 2%; and melanoma, 35%). (B) Relative proportions of distinct classifications of BRAF alterations across multiple cancer types (green = Class I, red = Class II, yellow = Class III, teal = structural rearrangement, and gray = unclassified).
Credit
2024 Toye et al.
Usage Restrictions
Original content
License
Original content